GLP-1 Agonist·Endocrinology - Insulins & Injectables

Exenatide

Type 2 Diabetes Mellitus

Authority requiredPBSGLP-1Byetta (BD), Bydureon (Weekly)Pre-filled pens for SC injec…+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

2 mg/week (XR)

Half-life

2.4 h (IR)

Weight Loss

POTENT

Caution: Pancreatitis

RISK

Cautions

Avoid / Cautions

Severe renal impairment (eGFR < 30), history of pancreatitis, severe gastroparesis. Pregnancy Category C.

Where it stands

Rapid Summary

Overview

The original GLP-1 receptor agonist (derived from Gila monster saliva). Suppresses appetite, slows gastric emptying, and forces glucose-dependent insulin release.

Clinical Focus

Highly dependent on renal clearance. Strictly contraindicated in severe renal failure.

Bottom Line

Exenatide is a GLP-1 receptor agonist for type 2 diabetes with weight loss benefits, but requires injection and causes significant nausea initially.

Formulation & Access

Brand Names

Byetta (BD), Bydureon (Weekly)

Parenteral

Pre-filled pens for SC injection.

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Type 2 Diabetes Mellitus.

Clinical Place

Largely superseded by Semaglutide and Dulaglutide due to their superior cardiovascular benefits and easier administration, but still used.

Quick reference

Class & Role

GLP-1 Agonist — The original GLP-1 receptor agonist (derived from Gila monster saliva).

Route / Formulation

Pre-filled pens for SC injection. (Byetta (BD), Bydureon (Weekly))

Usual Dose & Max

SC 5 mcg BD (within 60 mins BEFORE morning and evening meals). Titrate to 10 mcg BD after 1 month. Max 20 mcg/day (Byetta BD) OR 2 mg/week (Bydureon XR).

Key Indication Doses

Type 2 Diabetes (Immediate Release): SC 5 mcg BD (within 60 mins BEFORE morning and evening meals). Titrate to 10 mcg BD after 1 month. Type 2 Diabetes (Extended Release): SC 2 mg ONCE WEEKLY (Bydureon). Renal Impairment: Avoid entirely if eGFR < 30.

Best Uses

Exenatide is a GLP-1 receptor agonist for type 2 diabetes with weight loss benefits, but requires injection and causes significant nausea initially.

Key Risks

Gastrointestinal: Nausea (very common, affects > 40%), vomiting, diarrhea. CRITICAL — Acute pancreatitis. Renal: Acute kidney injury (mostly secondary to severe dehydration from vomiting/nausea). Metabolic: Zero inherent hypoglycemia risk (unless combined with insulin/sulfonylureas). Excellent weight loss.

Key Interactions

Because it paralyzes the stomach (slows gastric emptying), it can severely delay the absorption of oral drugs that require rapid peak levels (e.g., Paracetamol, oral contraceptives, antibiotics).

Monitoring

Warn patient to report severe, radiating upper abdominal pain with vomiting immediately (Pancreatitis). Routine HbA1c, U&E, and Weight.

Clinical Pearl

Nausea is the primary reason patients quit. Reassure them that the nausea is mostly mediated by the brain (CTZ) adjusting to the hormone and usually fades significantly after 4-8 weeks.

Access

Authority requiredByetta (BD), Bydureon (Weekly)

Brand: Byetta (BD), Bydureon (Weekly)
PBS status: Authority required

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.

GLP-1 Agonist·Endocrinology - Insulins & Injectables

Exenatide

Type 2 Diabetes Mellitus

Authority requiredPBSGLP-1Byetta (BD), Bydureon (Weekly)Pre-filled pens for SC injec…+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

2 mg/week (XR)

Half-life

2.4 h (IR)

Weight Loss

POTENT

Caution: Pancreatitis

RISK

Cautions

Avoid / Cautions

Severe renal impairment (eGFR < 30), history of pancreatitis, severe gastroparesis. Pregnancy Category C.

Where it stands

Rapid Summary

Overview

The original GLP-1 receptor agonist (derived from Gila monster saliva). Suppresses appetite, slows gastric emptying, and forces glucose-dependent insulin release.

Clinical Focus

Highly dependent on renal clearance. Strictly contraindicated in severe renal failure.

Bottom Line

Exenatide is a GLP-1 receptor agonist for type 2 diabetes with weight loss benefits, but requires injection and causes significant nausea initially.

Formulation & Access

Brand Names

Byetta (BD), Bydureon (Weekly)

Parenteral

Pre-filled pens for SC injection.

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Type 2 Diabetes Mellitus.

Clinical Place

Largely superseded by Semaglutide and Dulaglutide due to their superior cardiovascular benefits and easier administration, but still used.

Quick reference

Class & Role

GLP-1 Agonist — The original GLP-1 receptor agonist (derived from Gila monster saliva).

Route / Formulation

Pre-filled pens for SC injection. (Byetta (BD), Bydureon (Weekly))

Usual Dose & Max

SC 5 mcg BD (within 60 mins BEFORE morning and evening meals). Titrate to 10 mcg BD after 1 month. Max 20 mcg/day (Byetta BD) OR 2 mg/week (Bydureon XR).

Key Indication Doses

Best Uses

Exenatide is a GLP-1 receptor agonist for type 2 diabetes with weight loss benefits, but requires injection and causes significant nausea initially.

Key Risks

Key Interactions

Because it paralyzes the stomach (slows gastric emptying), it can severely delay the absorption of oral drugs that require rapid peak levels (e.g., Paracetamol, oral contraceptives, antibiotics).

Monitoring

Warn patient to report severe, radiating upper abdominal pain with vomiting immediately (Pancreatitis). Routine HbA1c, U&E, and Weight.

Clinical Pearl

Nausea is the primary reason patients quit. Reassure them that the nausea is mostly mediated by the brain (CTZ) adjusting to the hormone and usually fades significantly after 4-8 weeks.

Access

Authority requiredByetta (BD), Bydureon (Weekly)

Brand: Byetta (BD), Bydureon (Weekly)
PBS status: Authority required

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.